Michael S. Greenfield is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Greenfield's practice primarily comprises patent procurement, client counseling (rendering patent validity, infringement, and clearance opinions), and due diligence, all with special emphasis in the chemical and biotechnology arts. Dr. Greenfield has had primary responsibility for managing and prosecuting several patent portfolios of hundreds of patent applications filed worldwide. These portfolios have been licensed or sold for more than $2 billion (cumulative). Dr. Greenfield has advised his clients on technologies ranging from pharmaceutical chemistry, including small molecules, oligopeptides (both antisense and siRNA), and recombinant protein chemistry, to analyte detection and quantification using surface plasmon emission and absorption as well as immunoassays, NMR techniques, mass spectrometry, vaccines, recombinant DNA technologies, polymer chemistry and manufacture, business methods and mechanical devices. Dr. Greenfield's work has appeared in several articles in leading legal and scientific journals.
"The Doctrine of Equivalents: What's Left After Festo, Johnston & Johnson, and Sage Products?" 15 Intellectual Property & Technology Law Journal 5, October 2003
"Paradise Lost: The Uncertain Future of Research Tool Patents," 15 Intellectual Property & Technology Law Journal 1, March 2003
"Recombinant DNA Technology: A Science Struggling with the Patent Law", 44 Stanford Law Review 1051 (1992) (named one of the best intellectual property papers of the year, Intellectual Property Law Review, 1993)